Patents by Inventor Qunli Xu

Qunli Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240016795
    Abstract: Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2023
    Publication date: January 18, 2024
    Inventors: Sylvie GUICHARD, Maureen CALIGIURI, Anna ERICSSON, Qunli XU, Hesham MOHAMED
  • Patent number: 11801243
    Abstract: Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: October 31, 2023
    Assignee: Forma Therapeutics, Inc.
    Inventors: Sylvie Guichard, Maureen Caligiuri, Anna Ericsson, Qunli Xu, Hesham Mohamed
  • Publication number: 20230321097
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: November 17, 2022
    Publication date: October 12, 2023
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Publication number: 20220088005
    Abstract: Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 24, 2022
    Inventors: Sylvie GUICHARD, Maureen CALIGIURI, Anna ERICSSON, Qunli XU, Hesham MOHAMED
  • Publication number: 20200316067
    Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer.
    Type: Application
    Filed: June 1, 2020
    Publication date: October 8, 2020
    Inventors: Viviana Bozon, Katherine M. Galvin, Rachael L. Brake, Qunli Xu, Karuppiah Kannan
  • Publication number: 20200147080
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: July 23, 2019
    Publication date: May 14, 2020
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Patent number: 10426782
    Abstract: The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: October 1, 2019
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Rachael L. Brake, Viviana Bozon, Ching-Kuo J. Chow, James C. Dinunzio, Katherine M. Galvin, Karuppiah Kannan, Yuki Kodono, Qunli Xu
  • Patent number: 10406158
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: September 10, 2019
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Publication number: 20190117652
    Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 25, 2019
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Viviana BOZON, Katherine M. GALVIN, Rachael L. BRAKE, Qunli XU, Karuppiah KANNAN
  • Publication number: 20190046531
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: April 2, 2018
    Publication date: February 14, 2019
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Patent number: 9962385
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: May 8, 2018
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Publication number: 20170173033
    Abstract: The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.
    Type: Application
    Filed: March 26, 2015
    Publication date: June 22, 2017
    Inventors: Rachael L. BRAKE, Viviana BOZON, Ching-Kuo J. CHOW, James C. DINUNZIO, Katherine M. GALVIN, Karuppiah KANNAN, Yuki KODONO, Qunli XU
  • Publication number: 20160346282
    Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
    Type: Application
    Filed: February 6, 2015
    Publication date: December 1, 2016
    Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
  • Patent number: 6545128
    Abstract: The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid molecules complementary thereto (SEQ ID NO: 2 and SEQ ID NO: 5, respectively), portions of such nucleic acid molecules, vectors containing the nucleic acid molecules, and host cells containing the vectors. The invention also provides methods of using such nucleic acid molecules to identify the presence of a nucleic acid molecule encoding a Bax inhibitor protein in a sample or to increase or decrease the level of expression of a Bax inhibitor protein in a cell. In addition, the invention provides substantially purified BI-1 (SEQ ID NO: 3) and BI-2 (SEQ ID NO: 6) polypeptides, portions of such polypeptides, and antibodies specific for BI-1 or BI-2.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: April 8, 2003
    Assignee: The Burnham Institute
    Inventors: John C. Reed, Qunli Xu
  • Patent number: 6130317
    Abstract: The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid molecules complementary thereto (SEQ ID NO: 2 and SEQ ID NO: 5, respectively), portions of such nucleic acid molecules, vectors containing the nucleic acid molecules, and host cells containing the vectors. The invention also provides methods of using such nucleic acid molecules to identify the presence of a nucleic acid molecule encoding a Bax inhibitor protein in a sample or to increase or decrease the level of expression of a Bax inhibitor protein in a cell. In addition, the invention provides substantially purified BI-1 (SEQ ID NO: 3) and BI-2 (SEQ ID NO: 6) polypeptides, portions of such polypeptides, and antibodies specific for BI-1 or BI-2.
    Type: Grant
    Filed: July 15, 1998
    Date of Patent: October 10, 2000
    Assignee: The Burnham Institute
    Inventors: John C. Reed, Qunli Xu
  • Patent number: 5837838
    Abstract: The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid molecules complementary thereto (SEQ ID NO: 2 and SEQ ID NO: 5, respectively), portions of such nucleic acid molecules, vectors containing the nucleic acid molecules, and host cells containing the vectors. The invention also provides methods of using such nucleic acid molecules to identify the presence of a nucleic acid molecule encoding a Bax inhibitor protein in a sample or to increase or decrease the level of expression of a Bax inhibitor protein in a cell. In addition, the invention provides substantially purified BI-1 (SEQ ID NO: 3) and BI-2 (SEQ ID NO: 6) polypeptides, portions of such polypeptides, and antibodies specific for BI-1 or BI-2.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: November 17, 1998
    Assignee: The Burnham Institute
    Inventors: John C. Reed, Qunli Xu